Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | on 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 02.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 26.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 23.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
Stammdaten
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Unternehmen & Branche
| Name | Monte Rosa Therapeutics, Inc. |
|---|---|
| Ticker | GLUE |
| CIK | 0001826457 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,22 Mrd. USD |
| Beta | 1,64 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -38,626,000 | 448,659,000 | 233,056,000 | ||
| 2025-09-30 | 10-Q | -27,081,000 | 459,841,000 | 245,837,000 | ||
| 2025-06-30 | 10-Q | -12,295,000 | 359,586,000 | 268,080,000 | ||
| 2025-03-31 | 10-Q | 46,885,000 | 393,199,000 | 275,160,000 | ||
| 2024-12-31 | 10-K | -72,700,000 | 438,732,000 | 222,936,000 | ||
| 2024-09-30 | 10-Q | -23,859,000 | 315,080,000 | 205,457,000 | ||
| 2024-06-30 | 10-Q | -30,310,000 | 344,114,000 | 224,671,000 | ||
| 2024-03-31 | 10-Q | -31,968,000 | 266,746,000 | 152,519,000 | ||
| 2023-12-31 | 10-K | -135,352,000 | 303,755,000 | 179,250,000 | ||
| 2023-09-30 | 10-Q | -34,884,000 | 252,103,000 | 184,524,000 | ||
| 2023-06-30 | 10-Q | -35,178,000 | 278,616,000 | 213,654,000 | ||
| 2023-03-31 | 10-Q | -32,038,000 | 309,028,000 | 243,726,000 | ||
| 2022-12-31 | 10-K | -108,501,000 | 342,389,000 | 271,413,000 | ||
| 2022-09-30 | 10-Q | -27,318,000 | 357,603,000 | 291,092,000 | ||
| 2022-06-30 | 10-Q | -26,469,000 | 365,056,000 | 302,050,000 | ||
| 2022-03-31 | 10-Q | -23,932,000 | 346,005,000 | 325,875,000 | ||
| 2021-12-31 | 10-K | -73,958,000 | 366,329,000 | 347,515,000 | ||
| 2021-09-30 | 10-Q | -19,837,000 | 384,049,000 | 369,305,000 | ||
| 2021-06-30 | 10-Q | -18,405,000 | 368,941,000 | 356,678,000 | ||
| 2021-03-31 | 10-Q | -12,276,000 | -60,616,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | Warmuth Markus | Director, Officer, President & CEO | Open Market Sale | -8,000 | 17.64 | -141,124.80 | -167,9% | |
| 2026-04-09 | Nickson Philip | Officer, Chief Business & Legal Officer | Open Market Sale | -5,845 | 17.69 | -103,412.66 | -123,0% | |
| 2026-03-02 | Warmuth Markus | Director, Officer, President & CEO | Open Market Sale | -5,466 | 17.92 | -97,974.22 | -116,6% | |
| 2026-01-07 | Warmuth Markus | Director, Officer, President & CEO | Open Market Sale | -3,707 | 23.24 | -86,158.84 | -102,5% | |
| 2026-01-07 | Warmuth Markus | Director, Officer, President & CEO | Open Market Sale | -309 | 24.57 | -7,593.24 | -9,0% | |
| 2026-01-07 | Warmuth Markus | Director, Officer, President & CEO | Open Market Sale | -1,450 | 23.88 | -34,620.49 | -41,2% | |
| 2026-01-05 | Warmuth Markus | Director, Officer, President & CEO | Open Market Sale | -10,135 | 15.17 | -153,747.95 | -182,9% | |
| 2026-01-05 | Nickson Philip | Officer, Chief Business & Legal Officer | Open Market Sale | -3,155 | 15.17 | -47,861.35 | -56,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.